In this update on the recruitment efforts for AURORAX-0087A (AUR87A), Elypta is happy to confirm that in recent months the study has accomplished a number of positive milestones.
Despite the difficulties posed by the ongoing pandemic, the regulatory, contractual and set-up activities for all 16 clinical Sites included in the study have now been completed. Therefor, all 16 Sites are now actively recruiting to the study.
Thanks to the continuous commitment and efforts from all Principal Investigators, Site Team staff, the Contract Research Organization and our collaborators, AUR87A also reached the notable milestone of enrollment of the 100th patient to the study.
With 100 patients included, we have now reached > 70% recruitment target for Cohort 1. As of the end of June, AUR87A has screened more than 270 patients, and indeed 100 have fulfilled all eligibility for enrollment. The recruitment period is currently slated for completion in June 2022.
Elypta is also happy to confirm the acceptance of the abstract entitled “Patient perspective on serving on the steering committee of the AURORAX-0087A trial for non-metastatic clear cell renal cell carcinoma” at the Patient Engagement session of the European Association of Urology (EAU) 2021 Conference. Patient representation has been involved throughout the study and is included on the trial Steering Committee to monitor both result presentation as co-investigator. Elypta is proud for its collaboration with Dr. Rachel Giles at the International Kidney Cancer Coalition.
AUR87A is sponsored by the EU Horizon2020 SME Instrument phase 2 programme (Grant no 849251)
AURORAX-0087A (AUR87A) is a prospective multi-center observational in vitro diagnostics clinical validation cohort study to validate the diagnostic performance of free GAGome-based tests for the early detection of recurrence after curative intent surgery in patients with high or intermediate risk clear cell renal cell carcinoma.